JZJie Zhang

Jie Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jie Zhang has a total of 61 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Photobiomodulation Ameliorates Alexander Disease Through AMPK / mTOR ‐Mediated Mitophagy

    by Nianzhuang Qiu, Jie Zhang, Huan Yi, Sihan Dong, Lei Han, Zhendong Feng, Shumin Gao, Jie Shi, Jia Jia Liu, Ye Wu, et al.

    Alexander disease (AxD) is a rare neurodegenerative disorder characterized by the pathological accumulation of Rosenthal fibers (RFs) and astrocytic inflammation. Despite advances in elucidating its genetic basis, effective therapeutic strategies remain limited. Recent studies indicate that astrocytes in AxD exhibit excessive mitochondrial fragmentation, which may cause mitochondrial dysfunction and inflammatory response. Photobiomodulation (PBM) has been shown to improve mitochondrial function and exert anti‐inflammatory effects, suggesting it may be a promising candidate for the treatment of AxD. Here, we report that exposure to 1070‐nm infrared light exerts therapeutic efficacy in AxD. Specifically, using the astrocytes derived from AxD patients and a mouse model of AxD, we demonstrate that PBM regulates AMPK/mTOR signaling and promotes mitophagy, thereby attenuating reactive oxygen species production from fragmented mitochondria and subsequent inflammatory status. This study suggests PBM may serve as a novel, non‐invasive therapeutic approach for the treatment of AxD.

  • Efficacy of ketogenic diet therapy for pediatric drug-resistant epilepsy with monogenic etiology: A single-arm meta-analysis

    by Aidou Jiang, Wei Liu, Ying Liu, Jie Zhang

    Context: Drug-resistant epilepsy poses very difficult treatment challenges worldwide. Findings regarding the connection between ketogenic diet therapy (KDT) and genetic epilepsy are still unclear. Objective: In this meta-analysis we sought to examine the efficacy of KDT for drug-resistant epilepsy in patients with genetic mutations. Data Sources: The data were sourced from studies that reported KDT for epilepsy patients with monogenic etiology and were found in PubMed, Embase, Scopus, Web of Science, Cochrane Library, and 4 Chinese databases from database inception until January 2, 2024. Data Analysis: We determined that 50 studies involving a total of 849 patients who were treated with KDT met the eligibility criteria for inclusion. The meta-analysis revealed that the responder rate was 58% (95% CI, 49%-67%, I2 = 389%, P < .01) and the seizure-free rate was 29% (95% CI, 19%-39%, I2 = 86%, P < .01). In 40 reported studies, comprising 615 patients, specific gene mutations and response rates after KDT were mentioned. The highest responder rate, which occurred among patients with mutations in the solute carrier family 2 member 1 gene, SLC2A1 (n = 87), was 96% (95% CI, 91%-100%, I2 = 0%, P = .72), and the lowest, which occurred among patients with mutations of the sodium voltage-gated channel alpha subunit 8 gene, SCN8A (n = 5), was 15% (95% CI, 0%-60%, I2 = 39%, P = .20). In 39 studies, including 405 patients, specific gene mutations and seizure-free rates after KDT were reported. The highest seizure-free rate, which occurred in patients with mutations in SLC2A1 (n = 80), was 67% (95% CI, 49%-86%, I2 = 78%, P < .01), and the lowest seizure-free rates occurred in patients with mutations in the cyclin-dependent kinase-like 5 gene, CDKL5, (n = 40) and those with mutations in the potassium sodium-activated channel subfamily T member 1 gene, KCNT1 (n = 48), who had seizure-free rates of 0% (95% CI, 0%-6%, I2 = 0%, P = 1.00) and 2% (95% CI, 0%-7%, I2 = 0%, P = .82), respectively. The maximum efficacy of KDT, reflected by the responder rate (72%) and seizure-free rate (46%), was achieved at the 6-month follow-up, at which patients showed outcomes superior to those demonstrated at earlier or later assessments. Conclusions: The present meta-analysis revealed the efficacy of KDT in the treatment of genetic epilepsies, particularly in epilepsies associated with SLC2A1 and SCN1A mutations, but KDT had relatively poor efficacy in epilepsies related to CDKL5 and KCNT1 mutations. Notably, compared to other follow-up intervals, at the 6-month post-KDT follow-up interval patients showed the highest overall responder and seizure-free rates. Systematic Review Registration: PROSPERO registration No. CRD42024610852.


  • Open Access

    Confirmatory study on the retention rate of ketogenic diet therapy and related factors in children with drug‐resistant epilepsy: A single‐center cohort study

    by Jie Zhang, Qiang Gu, Yuan Wu, Han Xie, Cuijie Wei, Yao Zhang, Taoyun Ji, Xinhua Bao, Xingzhi Chang, Yuehua Zhang, et al.

    Objective: To confirm the retention rate of ketogenic diet therapy (KDT) in children with drug‐resistant epilepsy and identify its related factors through a cohort analysis. Methods: This was a single‐center cohort study. Baseline data were collected, and regular follow‐up was conducted after KDT treatment. The retention rate of KDT at different time points was determined. Cox regression analyses and other statistical methods were used to identify the factors related to the retention rate. Results: A total of 337 patients were included. 43.3% (146/337) of the patients had only spasms, 16.9% (57/337) had a genetic etiology, and 14.0% (47/337) had a structural etiology. Overall, 51.9% (175/337) of the patients were classified as having infantile epileptic spasm syndrome. The median age at KDT initiation was 33 months. 38.3% (129/337) of the patients responded to KDT. The retention rate of KDT at 3, 6, 12 and 24 months were 86.6% (292/337), 62.6% (211/337), 35.0% (118/337), and 20.2% (68/337), respectively. 9.9% (56/282) stopped the treatment due to unsatisfactory seizure control and 54.6% (154/282) stopped due to a non‐response. The retention rate in patients who responded to KDT was relatively greater than that in patients who did not respond to KDT [HR: 4.714 (95% CI: 3.493, 6.362), p < 0.001]. The retention rate of KDT at 3 months was associated with seizure type and anti‐seizure efficacy. The retention rate of KDT at 6 months was associated with seizure type, status epilepticus and anti‐seizure efficacy. The retention rate of KDT at 12 and 24 months were both associated with anti‐seizure efficacy. Significance: Anti‐seizure efficacy was the sole independent predictor of long‐term retention. This large‐scale cohort study advances the field by demonstrating the predominant role of efficacy in long‐term adherence. The cohort size ( N = 337), one of the largest reported, strengthens evidence that the long‐term retention rate (>1 year) can be used as an important indicator to evaluate the efficacy of KDT, which is simple and reliable.


  • Open Access

    Effects of the Small‐Molecule ISRIB on the Rapid and Efficient Myelination of Oligodendrocytes in Human Stem Cell‐Derived Cerebral Organoids in Patients With Leukoencephalopathy With Vanishing White Matter

    by Wei Yan, Jiong Deng, Jie Zhang, Kai Gao, Huan Yi, Junjiao Zhang, Fan Zhang, Jingmin Wang, Yuwu Jiang, Ye Wu

    Introduction: Leukoencephalopathy with vanishing white matter (VWM) is a rare genetic disorder caused by mutations in any one of the EIF2B 1–5, which encode subunits of eukaryotic translation initiation factor 2B (eIF2B). Previous studies suggested that the dysfunction of astrocytes played a central role in the pathogenic mechanism of VWM. In addition, eIF2B participates in the unfolded protein response(UPR) by coordinating the integrated stress response (ISR). Higher susceptibility to endoplasmic reticulum stress (ERS) and abnormal overactivation of the unfolded protein response (UPR) were found in VWM, which led to logical deterioration and exacerbation of cell death. There are currently no specific treatments available for VWM. Aim: Previous studies have successfully constructed three‐dimensional brain organoids that can be used to study the development of neuronal cells during brain development. In this study, we aimed to develop a more rapid and efficient brain organoid model that would produce mature astrocytes, oligodendrocytes, and myelin within 8 weeks. The small‐molecule ISR inhibitor (ISRIB) is a specific eIF2B activator by inhibiting the phosphorylation of eukaryotic translation initiation factor 2 (eIF2). Thus, ISRIB is used on eIF2B mutant organoids to determine its potential as a therapeutic approach for VWM. Results: We constructed EIF2B4 and EIF2B5 mutants as well as wild‐type rapid myelinating oligodendrocyte brain organoids using human induced pluripotent stem cells (iPSCs). We observed mature astrocytes, oligodendrocytes, and myelin within 8 weeks, greatly shortening the culture period. Compared with the wild type, mutant organoids displayed a smaller size and contained increased immature and dysfunctional astrocytes, oligodendrocytes, and sparse myelin. Abnormal overactivation of the UPR pathway was also present in mutant cerebral organoids. Additionally, we found that the maturation and function of these cells in mutant organoids were significantly improved after ISRIB treatment, which also inhibited hyperactivation of the unfolded protein response (UPR) signaling pathway. Conclusions: Our study established a rapid myelinating oligodendrocyte brain model in VWM for the first time, providing a more effective and tractable platform for further study of this condition and other white matter diseases. Furthermore, our findings suggested that ISRIB may have potential as a clinical treatment for VWM.


  • Open Access

    Morphological Characteristics and Extracellular Matrix Abnormalities in Astrocytes Derived From iPSCs of Children With Alexander Disease

    by Huan Yi, Jie Zhang, Kai Gao, Wei Yan, Hongyuan Chu, Junjiao Zhang, Fan Zhang, Yuwu Jiang, Jingmin Wang, Ye Wu

    Aims: Alexander disease (AxD) is a leukodystrophy caused by mutations in the astrocytic filament gene GFAP. There are currently no effective treatments for AxD. Previous studies have rarely established AxD models with the patient's original GFAP mutations. In this study, we aimed to explore the morphological and transcriptomic characteristics of GFAP‐mutant astrocytes via induced pluripotent stem cell (iPSC) models of AxD.Methods: Fibroblasts from three AxD children were reprogrammed into iPSCs. Wild‐type (WT) and AxD‐iPSCs were differentiated into astrocytes. We compared the morphological and transcriptomic differences between WT‐ and AxD iPSC–derived astrocytes.Results: Astrocytes induced from AxD‐derived iPSCs exhibited the Rosenthal fibers (RFs), the main pathological phenotype of AxD. Compared with WT astrocytes, AxD astrocytes had shorter processes, more branches, and larger cell bodies. Transcriptomic analysis revealed that extracellular matrix (ECM) components, particularly chondroitin sulfate proteoglycans (CSPGs), were upregulated, and ECM‐degrading enzymes were generally downregulated. These changes may lead to abnormalities in neurons and myelination.Conclusions: We explored the morphological characteristics of AxD astrocytes via iPSC models and revealed the ECM, previously unexplored for AxD, may be an important new pathogenic mechanism of this disease.


  • Open Access

    Clinical features of unilateral multilobar and hemispheric polymicrogyria (PMG)‐related epilepsy and seizure outcome with different treatment options

    by Pengxia Wu, Qingzhu Liu, Xianyu Liu, Yu Sun, Jie Zhang, Ruofan Wang, Taoyun Ji, Shuang Wang, Xiaoyan Liu, Yuwu Jiang, et al.

    Objective: To provide evidence for choosing surgical or nonsurgical treatment for epilepsy in patients with unilateral multilobar and hemispheric polymicrogyria (PMG).Methods: We searched published studies until September 2022 related to unilateral multilobar and hemispheric PMG and included patients who were followed up at the Pediatric Epilepsy Centre of Peking University First Hospital in the past 10 years. We summarized the clinical characteristics and compared the long‐term outcomes after surgical or nonsurgical (anti‐seizure medications, ASMs) treatment.Results: A total of 70 patients (49 surgical, 21 non‐surgical) with unilateral multilobar and hemispheric PMG were included. The median age at epilepsy onset was 2.5 years (1.0–4.1). The most common seizure types were focal and atypical absence seizures. In the whole cohort, 87.3% had hemiparesis and 67.1% had electrical status epilepticus during slow sleep (ESES). There were significant differences in age at epilepsy onset, extent of lesion, and EEG interictal discharges between the two groups. At the last follow‐up (median 14.1 years), the rates of seizure‐freedom (81.6% vs. 57.1%, p = 0.032) and ASM discontinuation (44.4% vs. 6.3%, p = 0.006) were higher in the surgical group than in the nonsurgical group. Patients in the surgical group had a higher rate of seizure‐freedom with complete resection/disconnection than with subtotal resection (87.5% vs. 55.6%, p = 0.078), but with no statistically significant difference. In the nonsurgical group, more extensive lesions were associated with worse seizure outcomes. Cognition improved postoperatively in 90% of surgical patients.Significance: In patients with unilateral multilobar and hemispheric PMG, the age of seizure onset, the extent of the lesion and EEG features can help determine whether surgery should be performed early. Additionally, surgery could be more favorable for achieving seizure freedom and cognitive improvement sooner.Plain Language Summary: We aim to summarize clinical characteristics and compare the long‐term outcomes after surgical and nonsurgical (ASM) treatment to provide a basis for treatment decisions for patients with unilateral multilobar and hemispheric polymicrogyria (PMG)‐related epilepsy. We found that patients with unilateral hemispheric and multilobar PMG had significantly higher rates of seizure freedom and ASM discontinuation with surgical treatment than with nonsurgical treatment. In the surgical group, seizure outcomes were better in patients treated with complete resection/disconnection than in those treated with subtotal resection, but the difference was not statistically significant.


  • Open Access

    Clinical characteristics and surgical outcomes in children with mild malformation of cortical development and oligodendroglial hyperplasia in epilepsy

    by Xianyu Liu, Ying Zhu, Qingzhu Liu, Shuang Zhang, Pengxia Wu, Yu Sun, Jie Zhang, Ruofan Wang, Taoyun Ji, Shuang Wang, et al.

    Objective: Mild malformation of cortical development with oligodendroglial hyperplasia in epilepsy (MOGHE) is a new and rare histopathological entity of cortical developmental malformations. The clinical characteristics of MOGHE remain challenging.Methods: Children with histologically confirmed MOGHE were retrospectively studied. The clinical findings, electroclinical and imaging features, and postoperative outcomes were analyzed, and previously published studies were reviewed up to June 2022.Results: Thirty‐seven children were included in our cohort. Clinical characteristics included early onset in infancy (94.6% before 3 years), multiple seizure types, and moderate or severe delay. Epileptic spasm is the most common seizure type and initial manifestation. The lesions were mainly multilobar (59.5% multiple lobes and 8.1% hemispheres), and predominance in the frontal lobe was observed. The interictal EEG pattern was circumscribed or widespread. The prominent MRI characteristics were cortical thickening, cortical/subcortical hyperintense T2/FLAIR signal, and blurring at the GM and WM transition. Among the 21 children followed up for more than 1 year after surgery, 76.2% were seizure‐free. Preoperative interictal circumscribed discharges and larger resections were significantly associated with a good postoperative outcome. The clinical features of 113 patients in the reviewed studies were similar to those we reported, but the lesions were mainly unilobar (73.5%) and Engel I was achieved in only 54.2% after surgery.Significance: Distinct clinical characteristics in MOGHE, especially age at onset, epileptic spasm, and age‐related MRI characteristics, can help in early diagnosis. Preoperative interictal discharge and surgical strategy may be predictors of postoperative outcomes.


  • Open Access

    Human‐induced pluripotent stem cell‐derived cerebral organoid of leukoencephalopathy with vanishing white matter

    by Jiong Deng, Jie Zhang, Kai Gao, Ling Zhou, Yuwu Jiang, Jingmin Wang, Ye Wu

    Introduction: Leukoencephalopathy with vanishing white matter (VWM) is a rare autosomal recessive leukoencephalopathy resulting from mutations in EIF2B1‐5, which encode subunits of eukaryotic translation initiation factor 2B (eIF2B). Studies have found that eIF2B mutation has a certain influence on embryonic brain development. So far, the effect of the eIF2B mutations on the dynamic process of brain development is not fully understood yet.Aims: Three‐dimensional brain organoid technology has promoted the study of human nervous system developmental diseases in recent years, providing a potential platform for elucidating the pathological mechanism of neurodevelopmental diseases. In this study, we aimed to investigate the effects of eIF2B mutation on the differentiation and development of different nerve cells during dynamic brain development process using 3D brain organoids.Results: We constructed eIF2B mutant and wild‐type brain organoid model with induced pluripotent stem cell (iPSC). Compared with the wild type, the mutant brain organoids were significantly smaller, accompanied by increase in apoptosis, which might be resulted from overactivation of unfolded protein response (UPR). Neuronal development was delayed in early stage, but with normal superficial neuronal differentiation in later stage. eIF2B mutations resulted in immature astrocytes with increased expression of GFAPδ, nestin, and αB‐crystallin, and there were increased oligodendrocyte progenitor cells, decreased mature oligodendrocytes, and sparse myelin in mutant cerebral organoids in the later stage.Conclusion: we constructed the first eIF2B mutant cerebral organoids to explore the dynamic brain development process, which provides a platform for further research on the specific pathogenesis of VWM.


  • Open Access

    Efficacy of ketogenic diet in CDKL5-related epilepsy: a single arm meta-analysis

    by Jie Zhang, Jiayi Ma, Xuting Chang, Pengxia Wu, Shangru Li, Ye Wu

    Background Drug-resistant epilepsy is one of the most important features of cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder. The ketogenic diet (KD) may be effective for patients with CDKL5-related epilepsy, but there is little high-quality evidence to confirm the efficacy. This meta-analysis investigated the efficacy and safety of KD in CDKL5-related epilepsy. Methods The PubMed, Embase, Web of Science, Cochrane Library, WanFang, CNKI and VIP databases were searched for relevant studies published up to January 1, 2022. Two reviewers independently screened the literature according to inclusion and exclusion criteria and evaluated the bias risk of the included studies. Meta-analysis was performed using Review Manager 5.3 software. Results A total of 12 retrospective studies involving 193 patients met the inclusion criteria. Meta-analysis revealed that the definite responder rate to KD in the treatment of CDKL5-related epilepsy was 18.0% [95% CI (0.07, 0.67)], with no statistical heterogeneity among studies (I2 = 0%, P = 0.45). The clinical responder rate was 50.5% [95% CI (0.75, 1.39)], and there was no statistical heterogeneity among all studies (I2 = 46%, P = 0.05). Subgroup analysis showed that there was no significant difference in the clinical responder rate between the two groups with seizure onset age before and after 1 month (P = 0.14). Only one study mentioned adverse reactions, and the incidence of adverse reactions was 78.3% (18/23). Constipation and vomiting were the main manifestations, implying a high incidence of gastrointestinal adverse reactions. Conclusions The definite responder rate to KD in CDKL5-related epilepsy is 18%, and the gastrointestinal adverse reactions was probably common in these patients. All the studies included in the meta-analysis were retrospective, and most of them had small sample sizes. Additional high-quality studies are needed to confirm the efficacy and tolerance of KD in CDKL5-related epilepsy.

  • Somatic variants in new candidate genes identified in focal cortical dysplasia type II

    by Zhongbin Zhang, Kai Gao, Qingzhu Liu, Jiapeng Zhou, Xiyuan Li, Na Lang, Ming Liu, Tianshuang Wang, Jie Zhang, Hui Wang, et al.

    Summary: Objective: Focal cortical dysplasia type II (FCDII) is a malformation of cortex development commonly found in children with drug‐resistant epilepsy. FCDII has been associated with somatic mutations in mammalian target of rapamycin (mTOR)‐related pathway genes and an upregulation of mTOR. Somatic mutations were found in 10%‐63% of FCDII samples; the frequency of the mutant allele was 0.93%‐33.5%. This study aimed to find new candidate genes involved in FCDII.Methods: We collected resected FCD lesions, perilesional brain tissues, and peripheral blood from 17 children with pathologically confirmed FCDII. We performed whole exome sequencing and followed a set of screening and analysis strategies to identify potentially deleterious somatic variants (PDSVs) in brain‐expressed genes. We performed site‐specific amplicon sequencing to validate the results. We also performed an in vitro functional study on an IRS1 variant.Results: In six of 17 samples, we identified seven PDSVs in seven genes, including two frameshift variants and five missense variants. The frequencies of the variant allele were 1.29%‐5.50%. The genes were MTOR, TSC2, IRS1, RAB6B, RALA, HTR6, and ZNF337. PDSVs in IRS1, RAB6B, ZNF337, RALA, and HTR6 had not been previously associated with FCD. In one lesion, two PDSVs were found in two genes. In a transfected cell line, we demonstrated that the c.1791dupG (identified in FCDII from Patient 1) led to a truncated IRS1 and significant mTOR hyperactivation compared to cells that carried wild‐type IRS1. mTOR was also activated in FCDII tissue from Patient 1.Significance: Seven PDSVs were identified in FCDII lesions in six of 17 children. Five variant genes had not been previously associated with cortical malformations. We demonstrated that the IRS1 variant led to mTOR hyperactivation in vitro. Although functional experiments are needed, the results provide evidence for novel candidate genes in the pathogenesis of FCDII.